Atara Biotherapeutics to Participate at the Stifel Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that AJ Joshi, MD, Chief Medical Officer, and Utpal Koppikar, Chief Financial Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York on Wednesday, November 16, 2022, at 1:50 p.m. EST
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov 9, 2022--
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that AJ Joshi, MD, Chief Medical Officer, and Utpal Koppikar, Chief Financial Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York on Wednesday, November 16, 2022, at 1:50 p.m. EST.
A live webcast of the fireside chat will be available by visiting the Investor Events and Presentations section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. ( @Atarabio ) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program receiving a CHMP positive opinion for a marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in Southern California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20221109005932/en/
CONTACT: INVESTORS & MEDIA:
Investors
Eric Hyllengren
805-395-9669
ehyllengren@atarabio.comMedia
Alex Chapman
805-456-4772
achapman@atarabio.com
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS RESEARCH SCIENCE BIOTECHNOLOGY
SOURCE: Atara Biotherapeutics, Inc.
Copyright Business Wire 2022.
PUB: 11/09/2022 04:01 PM/DISC: 11/09/2022 04:02 PM
http://www.businesswire.com/news/home/20221109005932/en
